In the EAE model, the repeated intrathecal administration of anti-HuR antisense oligonucleotide (ASO) reduced the main behavioral symptoms in mice, which reproduced the main clinical signs seen in MS patients [89]. The gene discussed is ELAVL1; the disease is myeloid sarcoma.